J Allergy Clin Immunol Pract:糠酸氟替卡松鼻喷雾剂在中度至重度、持续性、常年性过敏性鼻炎患者中的按需使用与常规使用的比较

2020-10-18 AlexYang MedSci原创

鼻内皮质类固醇(INCS)治疗常年性过敏性鼻炎(PAR)均建议定期使用。然而,还没有研究评估 "按需 "使用。最近,有研究人员比较了中度至重度PAR患者按需使用和定期使用INCS的疗效情况。


鼻内皮质类固醇(INCS)治疗常年性过敏性鼻炎(PAR)均建议定期使用。然而,还没有研究评估 "按需 "使用。最近,有研究人员比较了中度至重度PAR患者按需使用和定期使用INCS的疗效情况。

在一项为期6周的随机对照试验中,参与者被分配到糠酸氟替卡松(FF)鼻腔喷雾剂(27.5μg),每天2次喷雾,持续1周,然后再按需使用(FF-as-needed)5周,或每天2次喷雾,持续6周(FF-regular)。主要结果是鼻部症状总分(TNSS)的变化。次要结果是鼻腔吸气峰流量(NPIF)、鼻结膜炎生活质量-36问卷评分(RCQ-36)和累计FF剂量的变化。研究共包括了103名患者完成了研究,其中51名按需使用FF,52名定期使用FF。研究发现,第6周两组TNSS平均变化差异不显著(1.21分;95%CI,-0.08~2.49;P=0.066)。FF-常规组的TNSS趋向于较大的改善。FF常规组在第6周的NPIF平均变化高于FF按需组(-19.21 L/min;95%CI,-33.54,-4.89;P=0.009)。两组的RCQ-36改善情况相似。FF按需组的平均累计FF剂量是FF常规组的51%。

最后,研究人员指出,按需使用和定期使用INCS对PAR患者的TNSS和RCQ-36有相似的改善。但按需使用的INCS累积量是常规使用的一半。

原始出处:

Torpong Thongngarm , Chamard Wongsa , Phichayut Phinyo et al. As-needed Versus Regular Use of Fluticasone Furoate Nasal Spray in Patients With Moderate to Severe, Persistent, Perennial Allergic Rhinitis: A Randomized Controlled Trial. J Allergy Clin Immunol Pract. Oct 2020

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2047317, encodeId=b285204e31768, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Jan 12 17:32:40 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922609, encodeId=45ce192260937, content=<a href='/topic/show?id=3f3156324ff' target=_blank style='color:#2F92EE;'>#持续性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56324, encryptionId=3f3156324ff, topicName=持续性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Fri Jul 16 04:32:40 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796927, encodeId=859f1e96927ef, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22146, encryptionId=bf162214668, topicName=中度至重度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Feb 11 19:32:40 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041988, encodeId=04c2204198887, content=<a href='/topic/show?id=987b103432fe' target=_blank style='color:#2F92EE;'>#鼻喷雾剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103432, encryptionId=987b103432fe, topicName=鼻喷雾剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Jul 28 02:32:40 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894342, encodeId=c8fe89434220, content=学习!, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sun Oct 25 15:24:05 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329425, encodeId=a6bb1329425f7, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Oct 20 06:32:40 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568827, encodeId=c15e156882eb7, content=<a href='/topic/show?id=dc1d6392e50' target=_blank style='color:#2F92EE;'>#氟替卡松#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63927, encryptionId=dc1d6392e50, topicName=氟替卡松)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=796d15449089, createdName=海豹, createdTime=Tue Oct 20 06:32:40 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892927, encodeId=15eb89292ec3, content=每一种疾病都是可以量化的?如何评估治疗效果?也可以量化吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d005416790, createdName=ms4000000561534892, createdTime=Sun Oct 18 21:45:17 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892911, encodeId=00db8929116f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=534c5427090, createdName=ms7000000666306468, createdTime=Sun Oct 18 20:23:29 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892906, encodeId=cf99892906e7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200729/2ee0ca079ce64987b1195eb6aa20a1f4/ae923a98c9704879bacdc81d9fa7479a.jpg, createdBy=a3ab5398909, createdName=ms6000001113694287, createdTime=Sun Oct 18 19:20:28 CST 2020, time=2020-10-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2047317, encodeId=b285204e31768, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Jan 12 17:32:40 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922609, encodeId=45ce192260937, content=<a href='/topic/show?id=3f3156324ff' target=_blank style='color:#2F92EE;'>#持续性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56324, encryptionId=3f3156324ff, topicName=持续性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Fri Jul 16 04:32:40 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796927, encodeId=859f1e96927ef, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22146, encryptionId=bf162214668, topicName=中度至重度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Feb 11 19:32:40 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041988, encodeId=04c2204198887, content=<a href='/topic/show?id=987b103432fe' target=_blank style='color:#2F92EE;'>#鼻喷雾剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103432, encryptionId=987b103432fe, topicName=鼻喷雾剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Jul 28 02:32:40 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894342, encodeId=c8fe89434220, content=学习!, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sun Oct 25 15:24:05 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329425, encodeId=a6bb1329425f7, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Oct 20 06:32:40 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568827, encodeId=c15e156882eb7, content=<a href='/topic/show?id=dc1d6392e50' target=_blank style='color:#2F92EE;'>#氟替卡松#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63927, encryptionId=dc1d6392e50, topicName=氟替卡松)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=796d15449089, createdName=海豹, createdTime=Tue Oct 20 06:32:40 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892927, encodeId=15eb89292ec3, content=每一种疾病都是可以量化的?如何评估治疗效果?也可以量化吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d005416790, createdName=ms4000000561534892, createdTime=Sun Oct 18 21:45:17 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892911, encodeId=00db8929116f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=534c5427090, createdName=ms7000000666306468, createdTime=Sun Oct 18 20:23:29 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892906, encodeId=cf99892906e7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200729/2ee0ca079ce64987b1195eb6aa20a1f4/ae923a98c9704879bacdc81d9fa7479a.jpg, createdBy=a3ab5398909, createdName=ms6000001113694287, createdTime=Sun Oct 18 19:20:28 CST 2020, time=2020-10-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2047317, encodeId=b285204e31768, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Jan 12 17:32:40 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922609, encodeId=45ce192260937, content=<a href='/topic/show?id=3f3156324ff' target=_blank style='color:#2F92EE;'>#持续性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56324, encryptionId=3f3156324ff, topicName=持续性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Fri Jul 16 04:32:40 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796927, encodeId=859f1e96927ef, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22146, encryptionId=bf162214668, topicName=中度至重度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Feb 11 19:32:40 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041988, encodeId=04c2204198887, content=<a href='/topic/show?id=987b103432fe' target=_blank style='color:#2F92EE;'>#鼻喷雾剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103432, encryptionId=987b103432fe, topicName=鼻喷雾剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Jul 28 02:32:40 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894342, encodeId=c8fe89434220, content=学习!, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sun Oct 25 15:24:05 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329425, encodeId=a6bb1329425f7, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Oct 20 06:32:40 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568827, encodeId=c15e156882eb7, content=<a href='/topic/show?id=dc1d6392e50' target=_blank style='color:#2F92EE;'>#氟替卡松#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63927, encryptionId=dc1d6392e50, topicName=氟替卡松)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=796d15449089, createdName=海豹, createdTime=Tue Oct 20 06:32:40 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892927, encodeId=15eb89292ec3, content=每一种疾病都是可以量化的?如何评估治疗效果?也可以量化吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d005416790, createdName=ms4000000561534892, createdTime=Sun Oct 18 21:45:17 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892911, encodeId=00db8929116f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=534c5427090, createdName=ms7000000666306468, createdTime=Sun Oct 18 20:23:29 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892906, encodeId=cf99892906e7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200729/2ee0ca079ce64987b1195eb6aa20a1f4/ae923a98c9704879bacdc81d9fa7479a.jpg, createdBy=a3ab5398909, createdName=ms6000001113694287, createdTime=Sun Oct 18 19:20:28 CST 2020, time=2020-10-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2047317, encodeId=b285204e31768, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Jan 12 17:32:40 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922609, encodeId=45ce192260937, content=<a href='/topic/show?id=3f3156324ff' target=_blank style='color:#2F92EE;'>#持续性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56324, encryptionId=3f3156324ff, topicName=持续性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Fri Jul 16 04:32:40 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796927, encodeId=859f1e96927ef, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22146, encryptionId=bf162214668, topicName=中度至重度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Feb 11 19:32:40 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041988, encodeId=04c2204198887, content=<a href='/topic/show?id=987b103432fe' target=_blank style='color:#2F92EE;'>#鼻喷雾剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103432, encryptionId=987b103432fe, topicName=鼻喷雾剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Jul 28 02:32:40 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894342, encodeId=c8fe89434220, content=学习!, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sun Oct 25 15:24:05 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329425, encodeId=a6bb1329425f7, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Oct 20 06:32:40 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568827, encodeId=c15e156882eb7, content=<a href='/topic/show?id=dc1d6392e50' target=_blank style='color:#2F92EE;'>#氟替卡松#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63927, encryptionId=dc1d6392e50, topicName=氟替卡松)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=796d15449089, createdName=海豹, createdTime=Tue Oct 20 06:32:40 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892927, encodeId=15eb89292ec3, content=每一种疾病都是可以量化的?如何评估治疗效果?也可以量化吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d005416790, createdName=ms4000000561534892, createdTime=Sun Oct 18 21:45:17 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892911, encodeId=00db8929116f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=534c5427090, createdName=ms7000000666306468, createdTime=Sun Oct 18 20:23:29 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892906, encodeId=cf99892906e7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200729/2ee0ca079ce64987b1195eb6aa20a1f4/ae923a98c9704879bacdc81d9fa7479a.jpg, createdBy=a3ab5398909, createdName=ms6000001113694287, createdTime=Sun Oct 18 19:20:28 CST 2020, time=2020-10-18, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2047317, encodeId=b285204e31768, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Jan 12 17:32:40 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922609, encodeId=45ce192260937, content=<a href='/topic/show?id=3f3156324ff' target=_blank style='color:#2F92EE;'>#持续性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56324, encryptionId=3f3156324ff, topicName=持续性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Fri Jul 16 04:32:40 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796927, encodeId=859f1e96927ef, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22146, encryptionId=bf162214668, topicName=中度至重度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Feb 11 19:32:40 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041988, encodeId=04c2204198887, content=<a href='/topic/show?id=987b103432fe' target=_blank style='color:#2F92EE;'>#鼻喷雾剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103432, encryptionId=987b103432fe, topicName=鼻喷雾剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Jul 28 02:32:40 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894342, encodeId=c8fe89434220, content=学习!, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sun Oct 25 15:24:05 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329425, encodeId=a6bb1329425f7, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Oct 20 06:32:40 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568827, encodeId=c15e156882eb7, content=<a href='/topic/show?id=dc1d6392e50' target=_blank style='color:#2F92EE;'>#氟替卡松#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63927, encryptionId=dc1d6392e50, topicName=氟替卡松)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=796d15449089, createdName=海豹, createdTime=Tue Oct 20 06:32:40 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892927, encodeId=15eb89292ec3, content=每一种疾病都是可以量化的?如何评估治疗效果?也可以量化吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d005416790, createdName=ms4000000561534892, createdTime=Sun Oct 18 21:45:17 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892911, encodeId=00db8929116f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=534c5427090, createdName=ms7000000666306468, createdTime=Sun Oct 18 20:23:29 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892906, encodeId=cf99892906e7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200729/2ee0ca079ce64987b1195eb6aa20a1f4/ae923a98c9704879bacdc81d9fa7479a.jpg, createdBy=a3ab5398909, createdName=ms6000001113694287, createdTime=Sun Oct 18 19:20:28 CST 2020, time=2020-10-18, status=1, ipAttribution=)]
    2020-10-25 ms3000000449926787

    学习!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2047317, encodeId=b285204e31768, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Jan 12 17:32:40 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922609, encodeId=45ce192260937, content=<a href='/topic/show?id=3f3156324ff' target=_blank style='color:#2F92EE;'>#持续性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56324, encryptionId=3f3156324ff, topicName=持续性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Fri Jul 16 04:32:40 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796927, encodeId=859f1e96927ef, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22146, encryptionId=bf162214668, topicName=中度至重度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Feb 11 19:32:40 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041988, encodeId=04c2204198887, content=<a href='/topic/show?id=987b103432fe' target=_blank style='color:#2F92EE;'>#鼻喷雾剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103432, encryptionId=987b103432fe, topicName=鼻喷雾剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Jul 28 02:32:40 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894342, encodeId=c8fe89434220, content=学习!, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sun Oct 25 15:24:05 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329425, encodeId=a6bb1329425f7, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Oct 20 06:32:40 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568827, encodeId=c15e156882eb7, content=<a href='/topic/show?id=dc1d6392e50' target=_blank style='color:#2F92EE;'>#氟替卡松#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63927, encryptionId=dc1d6392e50, topicName=氟替卡松)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=796d15449089, createdName=海豹, createdTime=Tue Oct 20 06:32:40 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892927, encodeId=15eb89292ec3, content=每一种疾病都是可以量化的?如何评估治疗效果?也可以量化吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d005416790, createdName=ms4000000561534892, createdTime=Sun Oct 18 21:45:17 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892911, encodeId=00db8929116f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=534c5427090, createdName=ms7000000666306468, createdTime=Sun Oct 18 20:23:29 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892906, encodeId=cf99892906e7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200729/2ee0ca079ce64987b1195eb6aa20a1f4/ae923a98c9704879bacdc81d9fa7479a.jpg, createdBy=a3ab5398909, createdName=ms6000001113694287, createdTime=Sun Oct 18 19:20:28 CST 2020, time=2020-10-18, status=1, ipAttribution=)]
    2020-10-20 膀胱癌
  7. [GetPortalCommentsPageByObjectIdResponse(id=2047317, encodeId=b285204e31768, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Jan 12 17:32:40 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922609, encodeId=45ce192260937, content=<a href='/topic/show?id=3f3156324ff' target=_blank style='color:#2F92EE;'>#持续性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56324, encryptionId=3f3156324ff, topicName=持续性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Fri Jul 16 04:32:40 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796927, encodeId=859f1e96927ef, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22146, encryptionId=bf162214668, topicName=中度至重度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Feb 11 19:32:40 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041988, encodeId=04c2204198887, content=<a href='/topic/show?id=987b103432fe' target=_blank style='color:#2F92EE;'>#鼻喷雾剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103432, encryptionId=987b103432fe, topicName=鼻喷雾剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Jul 28 02:32:40 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894342, encodeId=c8fe89434220, content=学习!, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sun Oct 25 15:24:05 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329425, encodeId=a6bb1329425f7, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Oct 20 06:32:40 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568827, encodeId=c15e156882eb7, content=<a href='/topic/show?id=dc1d6392e50' target=_blank style='color:#2F92EE;'>#氟替卡松#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63927, encryptionId=dc1d6392e50, topicName=氟替卡松)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=796d15449089, createdName=海豹, createdTime=Tue Oct 20 06:32:40 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892927, encodeId=15eb89292ec3, content=每一种疾病都是可以量化的?如何评估治疗效果?也可以量化吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d005416790, createdName=ms4000000561534892, createdTime=Sun Oct 18 21:45:17 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892911, encodeId=00db8929116f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=534c5427090, createdName=ms7000000666306468, createdTime=Sun Oct 18 20:23:29 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892906, encodeId=cf99892906e7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200729/2ee0ca079ce64987b1195eb6aa20a1f4/ae923a98c9704879bacdc81d9fa7479a.jpg, createdBy=a3ab5398909, createdName=ms6000001113694287, createdTime=Sun Oct 18 19:20:28 CST 2020, time=2020-10-18, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=2047317, encodeId=b285204e31768, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Jan 12 17:32:40 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922609, encodeId=45ce192260937, content=<a href='/topic/show?id=3f3156324ff' target=_blank style='color:#2F92EE;'>#持续性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56324, encryptionId=3f3156324ff, topicName=持续性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Fri Jul 16 04:32:40 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796927, encodeId=859f1e96927ef, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22146, encryptionId=bf162214668, topicName=中度至重度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Feb 11 19:32:40 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041988, encodeId=04c2204198887, content=<a href='/topic/show?id=987b103432fe' target=_blank style='color:#2F92EE;'>#鼻喷雾剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103432, encryptionId=987b103432fe, topicName=鼻喷雾剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Jul 28 02:32:40 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894342, encodeId=c8fe89434220, content=学习!, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sun Oct 25 15:24:05 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329425, encodeId=a6bb1329425f7, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Oct 20 06:32:40 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568827, encodeId=c15e156882eb7, content=<a href='/topic/show?id=dc1d6392e50' target=_blank style='color:#2F92EE;'>#氟替卡松#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63927, encryptionId=dc1d6392e50, topicName=氟替卡松)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=796d15449089, createdName=海豹, createdTime=Tue Oct 20 06:32:40 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892927, encodeId=15eb89292ec3, content=每一种疾病都是可以量化的?如何评估治疗效果?也可以量化吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d005416790, createdName=ms4000000561534892, createdTime=Sun Oct 18 21:45:17 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892911, encodeId=00db8929116f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=534c5427090, createdName=ms7000000666306468, createdTime=Sun Oct 18 20:23:29 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892906, encodeId=cf99892906e7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200729/2ee0ca079ce64987b1195eb6aa20a1f4/ae923a98c9704879bacdc81d9fa7479a.jpg, createdBy=a3ab5398909, createdName=ms6000001113694287, createdTime=Sun Oct 18 19:20:28 CST 2020, time=2020-10-18, status=1, ipAttribution=)]
    2020-10-18 ms4000000561534892

    每一种疾病都是可以量化的?如何评估治疗效果?也可以量化吗?

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2047317, encodeId=b285204e31768, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Jan 12 17:32:40 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922609, encodeId=45ce192260937, content=<a href='/topic/show?id=3f3156324ff' target=_blank style='color:#2F92EE;'>#持续性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56324, encryptionId=3f3156324ff, topicName=持续性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Fri Jul 16 04:32:40 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796927, encodeId=859f1e96927ef, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22146, encryptionId=bf162214668, topicName=中度至重度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Feb 11 19:32:40 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041988, encodeId=04c2204198887, content=<a href='/topic/show?id=987b103432fe' target=_blank style='color:#2F92EE;'>#鼻喷雾剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103432, encryptionId=987b103432fe, topicName=鼻喷雾剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Jul 28 02:32:40 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894342, encodeId=c8fe89434220, content=学习!, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sun Oct 25 15:24:05 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329425, encodeId=a6bb1329425f7, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Oct 20 06:32:40 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568827, encodeId=c15e156882eb7, content=<a href='/topic/show?id=dc1d6392e50' target=_blank style='color:#2F92EE;'>#氟替卡松#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63927, encryptionId=dc1d6392e50, topicName=氟替卡松)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=796d15449089, createdName=海豹, createdTime=Tue Oct 20 06:32:40 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892927, encodeId=15eb89292ec3, content=每一种疾病都是可以量化的?如何评估治疗效果?也可以量化吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d005416790, createdName=ms4000000561534892, createdTime=Sun Oct 18 21:45:17 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892911, encodeId=00db8929116f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=534c5427090, createdName=ms7000000666306468, createdTime=Sun Oct 18 20:23:29 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892906, encodeId=cf99892906e7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200729/2ee0ca079ce64987b1195eb6aa20a1f4/ae923a98c9704879bacdc81d9fa7479a.jpg, createdBy=a3ab5398909, createdName=ms6000001113694287, createdTime=Sun Oct 18 19:20:28 CST 2020, time=2020-10-18, status=1, ipAttribution=)]
    2020-10-18 ms7000000666306468

    学习了

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2047317, encodeId=b285204e31768, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Jan 12 17:32:40 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922609, encodeId=45ce192260937, content=<a href='/topic/show?id=3f3156324ff' target=_blank style='color:#2F92EE;'>#持续性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56324, encryptionId=3f3156324ff, topicName=持续性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Fri Jul 16 04:32:40 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796927, encodeId=859f1e96927ef, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22146, encryptionId=bf162214668, topicName=中度至重度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Feb 11 19:32:40 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041988, encodeId=04c2204198887, content=<a href='/topic/show?id=987b103432fe' target=_blank style='color:#2F92EE;'>#鼻喷雾剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103432, encryptionId=987b103432fe, topicName=鼻喷雾剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Jul 28 02:32:40 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894342, encodeId=c8fe89434220, content=学习!, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sun Oct 25 15:24:05 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329425, encodeId=a6bb1329425f7, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Oct 20 06:32:40 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568827, encodeId=c15e156882eb7, content=<a href='/topic/show?id=dc1d6392e50' target=_blank style='color:#2F92EE;'>#氟替卡松#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63927, encryptionId=dc1d6392e50, topicName=氟替卡松)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=796d15449089, createdName=海豹, createdTime=Tue Oct 20 06:32:40 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892927, encodeId=15eb89292ec3, content=每一种疾病都是可以量化的?如何评估治疗效果?也可以量化吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d005416790, createdName=ms4000000561534892, createdTime=Sun Oct 18 21:45:17 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892911, encodeId=00db8929116f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=534c5427090, createdName=ms7000000666306468, createdTime=Sun Oct 18 20:23:29 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892906, encodeId=cf99892906e7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200729/2ee0ca079ce64987b1195eb6aa20a1f4/ae923a98c9704879bacdc81d9fa7479a.jpg, createdBy=a3ab5398909, createdName=ms6000001113694287, createdTime=Sun Oct 18 19:20:28 CST 2020, time=2020-10-18, status=1, ipAttribution=)]
    2020-10-18 ms6000001113694287

    学习了

    0

相关资讯

盘点:近期鼻炎治疗研究

【1】Asian Pac J Allergy Immunol:鼻内皮质激素治疗中度到重度阻塞性睡眠呼吸暂停且并发慢性鼻炎患者的效果研究

Int Arch Allergy Immunol:过敏性鼻炎儿童特异性舌下免疫治疗安全性的风险因素研究

良好的依从性往往归因于舌下免疫疗法(SLIT)的良好疗效和安全性。然而,很少有关于儿童SLIT治疗安全性的研究。

盘点:近期鼻炎研究

鼻炎即鼻腔炎性疾病,是病毒、细菌、变应原、各种理化因子以及某些全身性疾病引起的鼻腔黏膜的炎症。鼻炎的主要病理改变是鼻腔黏膜充血、肿胀、渗出、增生、萎缩或坏死等。梅斯医学小编整理了近期鼻炎的研究进展,与

盘点:鼻炎分子机制盘点

【1】Ann Allergy Asthma Immunol:过敏性鼻炎中抑制白介素35的表达和其诱导的调控T细胞能够促进II型先天性淋巴样细胞反应

BMC Public Health:气温变化对儿童过敏性鼻炎的影响

许多研究表明儿童呼吸系统疾病与短期温度变化有关,如昼夜温差和相邻两日之间的温度变化。然而,到目前为止,温度变化对过敏性鼻炎(AR)的影响还没有相关研究。最近,有研究人员评估了温度变化(即TCN和DTR

J Allergy Clin Immunol:300°IR舌下片是一种有效的、安全的治疗屋尘螨引起的过敏性鼻炎的方法

最近,有研究人员评估了屋尘螨:粉尘满 1:1提取物的300反应指数(IR)舌下片剂在中度至重度HDM诱导AR的青少年(年龄≥12岁)和成人中的疗效和安全性情况。